Literature DB >> 18383562

For the majority of patients with diabetes blood pressure and lipid management is not in line with recommendations. Results from a large population-based cohort in Germany.

Elke Raum1, Susanne Lietzau, Christa Stegmaier, H Brenner, Dietrich Rothenbacher.   

Abstract

OBJECTIVE: To evaluate the management of cardiovascular risk factors in a population-based cohort of adults with diabetes mellitus in Germany. DESIGN AND MEASUREMENTS: For the 9953 participants (50-74 years of age) of the ESTHER study, diabetes mellitus, hypertension, dyslipidemia and the respective medication were documented at baseline by their primary care physician. Blood pressure was taken and lipid levels were determined from a blood sample drawn at recruitment. Lifestyle factors (smoking, BMI, physical activity) were documented by the participants. Prevalence of pharmacotherapy for and control of hypertension and dyslipidemia among diabetic patients with these diagnoses were assessed and determinants were evaluated by multiple logistic regression.
RESULTS: Diabetes mellitus was present in 1375 participants (14.2%). Almost 78% of diabetic participants had physician diagnosed hypertension, 86.0% received pharmacotherapy, but only 12.8% of those with anti-hypertensive medication achieved blood pressure levels below 130/85 mmHg. Obese participants were more likely to receive anti-hypertensive pharmacotherapy than non-obese ones: adjusted odds ratio (OR, 95% confidence interval (CI)): 3.58 (1.86-6.87). Gender had no influence on anti-hypertensive pharmacotherapy. Older diabetic patients with hypertension were less likely to have sufficient blood pressure control than younger ones. Dyslipidemia was documented in 50% of diabetic patients. Diabetic participants with coronary heart disease or hypertension were more likely to receive lipid-lowering pharmacotherapy than those without these conditions (adjusted OR 1.85 (95%CI 1.19-2.89) and 2.59 (95%CI 1.41-4.74), respectively).
CONCLUSIONS: For most elderly with diabetes cardiovascular risk factor management continues to be not in line with recommendations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18383562     DOI: 10.1002/pds.1589

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  13 in total

1.  Prognostic value of haemoglobin A1c and fasting plasma glucose for incident diabetes and implications for screening.

Authors:  Ben Schöttker; Elke Raum; Dietrich Rothenbacher; Heiko Müller; Hermann Brenner
Journal:  Eur J Epidemiol       Date:  2011-09-27       Impact factor: 8.082

2.  Managing hypertension among nursing-home residents and community-dwelling elderly in Germany: a comparative pharmacoepidemiological study.

Authors:  Sophie Lochner; Wilhelm Kirch; Christoph Schindler
Journal:  Eur J Clin Pharmacol       Date:  2011-12-30       Impact factor: 2.953

3.  Improving clinician self-efficacy does not increase asthma guideline use by primary care clinicians.

Authors:  Michelle M Cloutier; Howard Tennen; Dorothy B Wakefield; Kevin Brazil; Charles B Hall
Journal:  Acad Pediatr       Date:  2012-05-26       Impact factor: 3.107

4.  Impact of obesity and bariatric surgery on survival.

Authors:  Nicolas V Christou
Journal:  World J Surg       Date:  2009-10       Impact factor: 3.352

5.  Evaluation of a toolkit to improve cardiovascular disease screening and treatment for people with type 2 diabetes: protocol for a cluster-randomized pragmatic trial.

Authors:  Baiju R Shah; Onil Bhattacharyya; Catherine Yu; Muhammad Mamdani; Janet A Parsons; Sharon E Straus; Merrick Zwarenstein
Journal:  Trials       Date:  2010-04-23       Impact factor: 2.279

6.  Evidence-based approach for managing hypertension in type 2 diabetes.

Authors:  Gerti Tashko; Robert A Gabbay
Journal:  Integr Blood Press Control       Date:  2010-05-24

7.  Guideline adherence in cardiovascular risk assessment and analysis in 15,000 hypertensive German patients in real life: results of the Prospective 3A Registry.

Authors:  Ralf Dechend; Edelgard Kaiser; Wolfgang Derer; Evelin Deeg; Andreas Busjahn; Roland E Schmieder; Uwe Zeymer
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-05-31       Impact factor: 3.738

8.  Changes in the prevalence, treatment and control of hypertension in Germany? A clinical-epidemiological study of 50.000 primary care patients.

Authors:  Alexander Michael Labeit; Jens Klotsche; Lars Pieper; David Pittrow; Franziska Einsle; Günter Karl Stalla; Hendrik Lehnert; Sigmund Silber; Andreas Michael Zeiher; Winfried März; Martin Wehling; Hans-Ulrich Wittchen
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

9.  Personal attributes that influence the adequate management of hypertension and dyslipidemia in patients with type 2 diabetes. Results from the DIAB-CORE Cooperation.

Authors:  Ina-Maria Rückert; Werner Maier; Andreas Mielck; Sabine Schipf; Henry Völzke; Alexander Kluttig; Karin-Halina Greiser; Klaus Berger; Grit Müller; Ute Ellert; Hannelore Neuhauser; Wolfgang Rathmann; Teresa Tamayo; Susanne Moebus; Silke Andrich; Christa Meisinger
Journal:  Cardiovasc Diabetol       Date:  2012-10-05       Impact factor: 9.951

10.  Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies.

Authors:  Ina-Maria Rückert; Michaela Schunk; Rolf Holle; Sabine Schipf; Henry Völzke; Alexander Kluttig; Karin-Halina Greiser; Klaus Berger; Grit Müller; Ute Ellert; Hannelore Neuhauser; Wolfgang Rathmann; Teresa Tamayo; Susanne Moebus; Silke Andrich; Christa Meisinger
Journal:  Cardiovasc Diabetol       Date:  2012-05-08       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.